SlowBull
The Business Brief FRIDAY, 4 SEPTEMBER 2026
← All stories
Markets

Trailing rivals, AbbVie scores win with dual-acting myeloma drug

1 source ·1 article ·1h ago

The drugmaker is leaning on a better side effect profile compared to drugs from J&J, Pfizer and Regeneron as it pushes etentamig toward FDA submission.

Covered by 1 outlet

Biopharmadive 1

All coverage · 1 article

BioPharma Dive ·1h ago

Trailing rivals, AbbVie scores win with dual-acting myeloma drug

The drugmaker is leaning on a better side effect profile compared to drugs from J&J, Pfizer and Regeneron as it pushes etentamig toward FDA submission.